Category Archives: Biotechnology

WASHINGTON--(BUSINESS WIRE)--

Mark J. Riedy, a Member of the Corporate & Securities Section and Energy & Clean Technology Practice at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., will give a plenary address at the World Congress on Biotechnology & Bioprocessing hosted by the Biotechnology Industrial Organization (BIO). The congress is being held April 29-May 2 in Orlando, Florida.

Mr. Riedy will be a featured speaker at the plenary session entitled, Financing Innovation in the Industrial Biotech Space: Creative Models and Future Trends. The panel will take place on Wednesday, May 2nd from 8:00 am to 10:00 am.

The BIO World Congress on Industrial Biotechnology and Bioprocessing is the world's largest industrial biotechnology event for business leaders, investors and policy makers. The 9th annual conference will bring together more than 1,000 attendees and feature presentations on the latest industry developments. The event will include more than 35 sessions led by biofuel and renewable chemical company executives, scientists and government officials.

In his more than 35 years of practice, Mr. Riedy has represented clients in domestic and international corporate finance matters, including energy and infrastructure, project development and debt and equity financing, mergers and acquisitions, technology outsourcing, investment fund structuring, venture capital structuring, and regulatory and legislative issues. He also has represented clients in international disputes before U.S. and foreign agencies, dealing with matters such as anti-dumping, export controls, sanctions, and anti-bribery. Mr. Riedy has counseled renewable and conventional energy and infrastructure clients doing business in more than 50 countries.

Mr. Riedy is one of the founders and general counsel of the American Council On Renewable Energy (ACORE), the largest domestic and international association of renewable energy and clean tech businesses. Over the years, he has lead the DC Technology Funders, a monthly breakfast meeting which brings together up to 40 venture capital and private equity funders for presentations by new clean tech companies seeking funding. Additionally, Mr. Riedy has served as general counsel and a longtime board member (currently board member emeritus) for the US-India Business Council, the largest U.S.-India business association, general counsel of the Clean Fuels Development Coalition and he is Vice Chairman of the American Bar Association's Project Finance Committee. He has the honor of an AV rating by Martindale-Hubbell and was recently named one of the Top 100 Bioenergy Leaders in the world by Biofuels Digest.

Mr. Riedy received his B.A., summa cum laude, from the University of Michigan and his J.D. from the Georgetown University Law Center.

For more information about BIOs World Congress on Biotechnology & Bioprocessing, please click here.

For more information about Mintz Levin, please click here.

Read more:
Mintz Levin Attorney Mark J. Riedy to Speak at World Congress on Biotechnology & Bioprocessing

EAST SETAUKET,N.Y., May 1, 2012 /PRNewswire/ --John S. Kovach, M.D., Chair, Board of Directors and CEO of Lixte Biotechnology Holdings, Inc. (LIXT.PK), announced the submission of an IND application to the Food and Drug Administration to conduct a Phase I trial of its lead, anti-cancer compound, LB-100.

Dr. Kovach said, "We believe that LB-100, a novel anti-cancer compound, prevents cancer cells from defending themselves against standard types of cancer treatments. In pre-clinical animal models of cancer, LB-100 inhibits cancer cell growth on its own but, more importantly, it significantly enhances the killing of cancer cells by several widely used anti-cancer drugs including Temozlomide, Doxorubicin, and Docetaxel as well as radiation. In the initial Phase I trial to be conducted at a nationally recognized comprehensive cancer center, LB-100 will be evaluated alone and in combination with a standard anti-cancer drug. We hope that the improved anti-cancer activity of LB-100 combined with conventional anti-cancer treatments in animal models is borne out in the clinic without undue toxicity. If so, we believe that regimens containing LB-100 will be associated with meaningful benefit to patients with a number of different types of cancer."

About Lixte Biotechnology Holdings, Inc. Lixte is engaged in development of improved treatments for cancer. The company was created to capitalize on opportunities to develop low cost, specific and sensitive tests for the early detection of cancers. Over the past four years, however, Lixte has evolved into what is now primarily a cancer drug discovery company, using biomarker technology to identify vulnerable anti-cancer targets and then create novel compounds to attack those targets.

The Company is developing new treatments for several cancers for which better treatments are urgently needed. The initial focus was on the most aggressive type of brain cancer of adults and children but now includes other cancers including breast, pancreas, stomach, and melanomas and sarcomas.

Forward-Looking StatementsThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto in the Quarterly Report on Form 10K for the year ending December 31, 2011.

For additional information, please see: http://www.Lixte.com

More:
Lixte Biotechnology Holdings Announces Submission of an IND to the FDA for Approval of a Clinical Trial of LB-100, a ...

Some business-minded folks in Charlottesville say there's a biotechnology boom happening in the city, one that could certainly bolster the bottom line for the economy in the area.

Those familiar with the industry's growth say Charlottesville may not be in the ranks of California's Silicon Valley or North Carolina's Research Triangle quite yet, but 35 thriving biotech companies have started up in the city so far, and they only anticipate more to come. The research and ideas coming from the University Of Virginia are being credited with being a huge push for biotechnology business starting up in Charlottesville.

Armed with test tubes and lab coats, scientists at INDOOR Biotechnologies spend their days testing out allergens in their small space on Harris Street, but they're gearing up for a big move. From bottling to biotechnology, CEO Martin Chapmanwill soon move his company into the old Coca Cola plant on Preston Avenue. He hopes to use that space to not only expand his own business, but also to help other science-based companies start up in the city.

"We've developed our plan around that, to develop it as a space for us and also an incubator new biotech companies," Chapman explained.

After taking his UVA research to his company, Chapman says what made him settle on Charlottesville is far from scientific. Rather, it's as simple as the resources and smarts the town has to offer him.

"Charlottesville attracts talented people," Chapman added.

Chapman says the success of INDOOR Biotechnologies is just one example of this industry's growth in the area. In fact, according to his count, about 35 biotech companies are providing more than 100 jobs to people in the city.

"Its happening and there's a lot of impetus in the industry at the moment to push things forward," Chapman said.

Helping to fuel the progress, UVA Innovation Partnerships Executive Director Mark Crowell says world-class research is great to have, but even better when companies are capitalizing on it.

"There's a lot of things we can do to sort of nurture the companies and nurture the community, attract the talent, retain the talent, and help the companies through that initial growth spurt," Crowell said.

Link:
Biotechnology Booming In Charlottesville

24-04-2012 05:39 Highlights of an industrial visit by a delegation of Thai technology-based entrepreneurs and scientists to booming biotechnology and IT industries in and around Bangalore. The one-week study visit took place in March 2012. It was partially supported by Thailand's Department of International Economic Affairs, Ministry of Foreign Affairs in cooperation with National Science and Technology Development Agency (NSTDA). The delegates visited Biocon, Infosys, Sartorius Stedim India, Metahelix Life Sciences, Bhat Bio-Tech India, Association of Biotechnology Led Enterprises (ABLE), Institute of Bioinformatics and Applied Biotechnology (IBAB), Visvesvaraya Industrial and Technological Museum, and Government of Karnataka's Department of Information Technology and Biotechnology. Sightseeing sites visited include Lal Bagh Botanical Garden, Brigade Road, MG Road, ISKCON Temple, Tipu Palace, Bangalore Palace, and Nandi Hills.

More:
Bangalore Biotechnology

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today its selection of Representative Mike Rogers (R-MI) as Legislator of the Year for 2011-2012. Representative Rogers receives the award in conjunction with todays BIO Legislative Day Fly-In reception.

"Representative Rogers' achievements on the Energy and Commerce Committee have been instrumental for the growth of the life science industry, which is researching and developing new cures and treatments for debilitating diseases, and providing cutting-edge technologies to improve crop yields, and discover cleaner forms of home-grown energy," said BIO President and CEO Jim Greenwood. We salute him for introducing and supporting critically important legislation, including the Pandemic and All Hazard Preparedness Act, the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act.

Representative Rogers has quickly established himself as a champion of the biotechnology industry, both here in Michigan and throughout America. We appreciate his consistent support for this industry that provides almost 40,000 high-paying jobs in this state alone," said Stephen Rapundalo, PhD, MichBio President & CEO.

More than 200 biotechnology industry representatives from 41 states will participate in hundreds of meetings with Members of the House and Senate during the BIO Legislative Day Fly-In.Participants will discuss issues critical to the biotechnology industry including reauthorization of the Prescription Drug User Fee Act, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act/Faster Access to Specialized Treatments (FAST) Act, adequate reimbursement for vital therapies under Medicare, and capital formation issues relevant to biotechnology companies.

Photos of the award presentation are available upon request.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

See more here:
Representative Rogers Honored as BIO Legislator of the Year

WASHINGTON--(BUSINESS WIRE)--

The Biotechnology Industry Organization (BIO) announced today its selection of Senator Michael Enzi (R-WY) as a Legislator of the Year for 2011-2012. Senator Enzi receives the award in conjunction with todays BIO Legislative Day Fly-In reception.

"As the ranking minority member of the Committee on Health, Education, Labor, and Pensions, Senator Enzi has been instrumental to the growth of the life science industry. Thanks to his support, American doctors and scientists are better able to translate innovative research into new cures and treatments for debilitating diseases, such as multiple sclerosis and HIV/AIDS, and provide cutting-edge technologies to improve crop yields, and discover cleaner forms of home-grown energy," said BIO President and CEO Jim Greenwood.As a champion of American biotechnology, his steadfast support for a timely reauthorization of the Prescription Drug User Fee Act, as well as efforts to ensure reforms to the Accelerated Approval pathway at the FDA, reflect a keen understanding of important healthcare issues.

More than 200 biotechnology industry representatives from 41 states will participate in hundreds of meetings with Members of the House and Senate during the BIO Legislative Day Fly-In.Participants will discuss issues critical to the biotechnology industry including reauthorization of the Prescription Drug User Fee Act, the Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act/Faster Access to Specialized Treatments (FAST) Act, adequate reimbursement for vital therapies under Medicare, and capital formation issues relevant to biotechnology companies.

Photos of the award presentation are available upon request.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the worlds largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Visit link:
Senator Enzi Honored as BIO Legislator of the Year